KOHLOVÁ, Barbora, Martin PISKÁČEK, Marie TOMANDLOVÁ, Veronika MOTÚZOVÁ, Vít ZMÁTLO, Vilém JURÁŇ, Marek SOVA, Václav VYBÍHAL, Pavel FADRUS, Tomáš KAZDA and Andrea KNIGHT. Gamma-delta T cells in Glioblastoma patients. In The 9th International γδ T Cell Conference. 2021.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Gamma-delta T cells in Glioblastoma patients
Authors KOHLOVÁ, Barbora, Martin PISKÁČEK, Marie TOMANDLOVÁ, Veronika MOTÚZOVÁ, Vít ZMÁTLO, Vilém JURÁŇ, Marek SOVA, Václav VYBÍHAL, Pavel FADRUS, Tomáš KAZDA and Andrea KNIGHT.
Edition The 9th International γδ T Cell Conference, 2021.
Other information
Original language English
Type of outcome Requested lectures
Field of Study 30204 Oncology
Country of publisher China
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Medicine
Keywords in English Gamma-delta T lymphocytes; Glioblastoma patients
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 21/12/2021 08:14.
Abstract
Gamma-delta (γδ) T cells are important effector lymphocytes of innate immunity with proven antitumour reactivity against aggressive glioblastoma brain tumour (GBM). Therapeutic approaches to GBM have had limited success particularly due to the protective brain barrier and the tumour immunosuppressive microenvironment. The GBM-infiltrating γδ T lymphocytes (TILs) have not been extensively investigated.In this study, we examined Vδ1 a Vδ2 γδ T cell populations in peripheral blood and paired tumour tissue samples from GBM patients (n=33) following the resection and throughtout the therapy follow-up. Tumour samples were processed using enzymatic kits and gentleMACSTM Dissociator (Miltenyi Biotec Inc.) and TIL γδ T cells were analyzed by flow cytometry.We found infiltration of both intratumoral CD3+ γδ T cell subsets in 73% tested tumour samples. We detected Vδ1 γδ T cell in the range 0-0.5% (median 0.26%). Majority of GBM patients presented the Vδ2 subset among TILs in the range 0- 12% (median 3.2%). Functional studies showed prominent cytotoxicity of magnetically sorted Vδ1 a Vδ2 γδ T cells against GBM cell lines and more importantly against primary tumours. Next, we identified the EphA2 receptor as one of the targets for tumour reactive Vδ1 γδ T cells. Specifically, we found that blocking of EphA2 expression resulted in significant inhibition of GBM tumour killing mediated by Vδ1 γδ T cells. Furthermore, multiplex analysis of soluble proteins by Luminex® 200™ in patients‘ plasma samples identified significantly elevated levels of MICA, check-point inhibitors B7-H3 (CD276), PD-L1 (B7-H1, CD274), Galectin-9 and Nectin-4. The patient’s clinical course, therapeutic protocols and RNAseq data will be discussed.
Links
NV19-05-00410, research and development projectName: Úloha cytotoxických gamma-delta T buněk na terapeutické rezistenci a recidivě Glioblastoma Multiforme
Investor: Ministry of Health of the CR
PrintDisplayed: 18/7/2024 14:33